Show simple item record

dc.contributor.authorVan Gelder, M.
dc.contributor.authorDe Wreede, L. C.
dc.contributor.authorBornhäuser, M.
dc.contributor.authorKansu, Emin
dc.date.accessioned2020-02-14T08:34:40Z
dc.date.available2020-02-14T08:34:40Z
dc.date.issued2017
dc.identifier.issn0268-3369
dc.identifier.urihttps://doi.org/10.1038/bmt.2016.282
dc.identifier.urihttps://www.scopus.com/inward/record.url?eid=2-s2.0-85014577257&partnerID=40&md5=c958280f2180cf2a518047e503b49fe6
dc.identifier.urihttp://hdl.handle.net/11655/22077
dc.description.abstractEven with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25–31), 35% (95% CI, 32–38) and 40% (95% CI, 37–42), respectively. Patients who passed the 5-year landmark event-free survival (N = 394) had a 79% probability (95% CI, 73–85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.tr_TR
dc.language.isoengtr_TR
dc.publisherMacmillan Publishers Limitedtr_TR
dc.relation.isversionof10.1038/bmt.2016.282tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectBloodtr_TR
dc.subjectMarrow transplantationtr_TR
dc.subjectCLLtr_TR
dc.subject.lcshKansertr_TR
dc.titleLong-Term Survival of Patients with Cll After Allogeneic Transplantation: A Report from the European Society for Blood and Marrow Transplantationtr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalBone Marrow Transplantationtr_TR
dc.contributor.departmentTemel Onkolojitr_TR
dc.identifier.volume52tr_TR
dc.identifier.issue3tr_TR
dc.identifier.startpage372tr_TR
dc.identifier.endpage380tr_TR
dc.indexingScopustr_TR
dc.fundingYoktr_TR


Files in this item

This item appears in the following Collection(s)

Show simple item record